AMD

Recapping a recent conversation led by Dilsher S. Dhoot, MD.

Modern Retina’s recent Case-Based Roundtable focused on next-generation treatments for retinal disease that provide advanced care for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).

A new study from China revealed a genetic link between coffee consumption and age-related macular degeneration (AMD).

Ocular Therapeutix showcases innovative TKI treatments for retinal diseases at the Clinical Trials Summit in Las Vegas, June 21, 2025.

The gift will be used to treat and potentially cure eye diseases like macular degeneration and glaucoma, increase focus on basic science, and harness artificial intelligence to revolutionize vision care.

Brazilian regulatory authority ANVISA grants marketing authorization for Ranivisio.

The new surgical technique incorporates a new surgical clamp that maintains eye pressure during the insertion of two tissue patches in immediate succession while minimizing damage to the surrounding tissue.

Join global experts at the 2025 International SPECTRALIS Symposium in Heidelberg, exploring innovations in ophthalmology and space-related ocular health.

Lineage Cell Therapeutics will be presenting data on the safety and tolerability of RG6501 (OpRegen) for the treatment of geographic atrophy, secondary to age-related macular degeneration during the upcoming Clinical Trials at the Summit 2025 meeting.

Ashvattha Therapeutics announced positive interim phase 2 results for migaldendranib for the treatment of AMD and DME.

SYL1801 is a treatment for neovascular macular degeneration administered via eye drops.

Valeda met the primary end point in the US LIGHTSIDE III trial, improving the best corrected visual acuity in patients for 24 months of >5 letters or equivalent to 1 line improvement on the eye chart, according to the company.

Optigo Biotherapeutics presents promising preclinical data at ARVO.

The trial assesses GAL-101 as an oral therapy designed to treat Alzheimer disease, dry age-related macular degeneration, and glaucoma.

The phase 2 clinical trial data evaluating the efficacy, safety, and dosing intervals of high-dose IBI302 were presented during the annual 2025 ARVO meeting.

The Retinal Genix plans to use the facility to further the development of its DNA/RNA/GPS Pharmaco-Genetic Mapping platform.

Authors of the study believe this potential will provide clinicians with valuable information about patient responses to treatment.

A decision on a longer dosing duration for the high-dose formulation is expected by April 20, 2025.

This agreement allows a launch in the US in the second half of 2026 or earlier in certain circumstances.

Compensation techniques in swept-source optical coherence tomography angiography improve accuracy by correcting signal loss from drusen and other artifacts.

The first session of the 2025 COPHy meeting was titled "Big controversies in retina and beyond in 2025.”

Researchers assessed the costs to patients and caregivers in Germany, Bulgaria and the US

This large study sought to determine if daily supplementation with cocoa extract, a source of flavanols, reduces the occurrence or progression of AMD.

The decision to discontinue the trials comes shortly after the announcement that COAST missed its primary endpoint.

The trial evaluated sozinibercept (2 mg) every 4 or 8 weeks in combination with aflibercept (2 mg), as per label, every 8 weeks after a loading phase for the treatment of wet AMD.

The investigators retrospectively evaluated 126 consecutive treatment-naïve nAMD patients (126 eyes) who received a loading dose of a minimum of three monthly intravitreal aflibercept injections that was followed by a TAE.

Among the promising areas of retinal disease research are innovative approaches targeting pan-vascular endothelial growth factor inhibition.